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This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discov-
ery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain se-
lection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, 
T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and 
lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current 
Chagas disease drug-discovery and development landscape.
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Chagas disease is a chronic, systemic, parasitic in-
fection caused by the protozoan Trypanosoma cruzi. 
According to estimates by the Pan American Health Or-
ganization and the World Health Organization (WHO), 
7.7-10 million people are chronically infected with T. 
cruzi and 10,000-14,000 deaths per year are caused by 
Chagas disease (Schofield et al. 2006, WHO 2013). Ap-
proximately 60-70% of the chronic patients have no clin-
ical symptoms (indeterminate form), whereas 30-40% 
either have or will develop cardiomyopathy, digestive 
megasyndromes or both. Chagas disease ranks among 
the world’s most neglected diseases and is considered 
to be the parasitic infection with the greatest socioeco-
nomic impact in Latin America, being responsible for an 
estimated US$ 1.2 billion in lost productivity annually 
(WHO 2012). In the last four decades, controlling vector 
and blood transfusion-transmission of T. cruzi has been 
successful in several endemic countries. However, other 
transmission mechanisms, such as congenital, trans-
plantation and oral, may sustain infection. Furthermore, 
population migration has caused Chagas disease to be a 
worldwide public health issue.
New treatments for Chagas disease are urgently 
needed. The only two drugs available, benznidazole 
(BZ) and nifurtimox (NF), require prolonged treatment, 
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are often poorly tolerated and have variable efficacy in 
the chronic phase of the disease, which is the predomi-
nant clinical presentation encountered (Rassi Jr et al. 
2012). The reasons for treatment failures are unknown, 
but may be due to different treatment evaluation meth-
ods, incomplete treatment administration, variable drug 
susceptibility among T. cruzi strains and characteristics 
of the host’s immune system (Urbina 2010). Neverthe-
less, several non-randomised clinical studies demon-
strate the efficacy of etiological treatment to reduce an-
tibody titres and the progression of chronic Chagas heart 
disease (Sosa-Estani et al. 2009). Two double-blind, 
placebo-controlled clinical trials with a large cohort of 
patients, TRAENA and BENEFIT (Figure), are assess-
ing whether BZ therapy improves prognosis for patients 
with chronic Chagas disease.
Following years of little progress in the research 
and development (R&D) of new drugs to treat Chagas 
disease, significant advances have recently been made 
with increased collaborations and partnerships in drug 
discovery and lead optimisation (Buckner 2011, WHO 
2012) (Figure). Upstream R&D activities include ef-
forts to increase the harmonisation and standardisa-
tion of drug screening protocols and the development 
of high throughput methodologies for in vitro testing. 
Novel chemical classes have shown promising activity 
against T. cruzi. Two Phase IIa clinical trials evaluat-
ing antiparasitic activity of the ergosterol biosynthesis 
inhibitors posaconazole and ravuconazole (E1224, pro-
drug) in chronic patients have recently been concluded 
(DNDi 2013, Molina et al. 2014), but with disappointing 
results. A cysteine protease (cruzipain) inhibitor (vinyl-
sulfone derivative K777), the 5-nitroimidazole fexinida-
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zole and a nontoxic fungicide fenarimol, among others, 
are in pre-clinical studies (Figure). Importantly, alterna-
tive treatment regimens are being considered, including 
combination therapies with available and new anti-T. 
cruzi drugs (Benaim et al. 2006, Bustamante et al. 2013, 
Diniz et al. 2013), with potential for synergy, better tol-
erability, avoidance of drug resistance and to provide 
backup drugs when resistance emerges.
T. cruzi genetic diversity - Recent new in vitro and in 
vivo drug screening protocols have included reference 
strains of T. cruzi. The selection of these strains has been 
largely pragmatic, based on availability and historical 
experience. However, previous experimental evidence 
in a murine model indicated that BZ and NF may ex-
hibit a broad range of divergent activities against differ-
ent T. cruzi strains (Filardi & Brener 1987, Neal & van 
Bueren 1988). A recent study described large variations 
in the response to ergosterol biosynthesis inhibitors in in 
vitro assays against a panel of T. cruzi strains and clones 
belonging to different genetic lineages (see below); in 
contrast, BZ and NF did not differ significantly in their 
efficacy against the same panel of strains and clones 
(Moraes et al. 2014). Whether the experimental data 
obtained in mice and in vitro with T. cruzi strains cor-
respond to the response to drugs in human hosts has not 
yet been established, partially because definitive criteria 
for curing Chagas disease are lacking. Nevertheless, the 
available evidence supports the proposition that assess-
ing the activity of new compounds against a representa-
tive panel of strains is essential.
This proposition takes into consideration the remark-
ably diverse multiplicity of T. cruzi genotypes and pheno-
types (Miles et al. 2009, Guhl & Ramírez 2011, Zingales 
et al. 2012), designated by consensus as comprising six T. 
cruzi discrete typing units TcI-TcVI (Zingales et al. 2009). 
The term ‘‘discrete typing unit’’ (DTU) was proposed to 
describe sets of stocks that are genetically more similar 
to one another than to any other stock and are identifiable 
by common molecular markers (Tibayrenc 1998).
Chagas disease drug discovery and development landscape in 2013/2014. Research activities: public and private partners are engaged in the 
screening of chemical libraries, hit to lead and lead optimisation of new series for Chagas disease treatment; Translational activities: pre-clinical 
studies, Phase I and IIa studies with new compounds are underway; Development activities: two double-blind, placebo-controlled clinical tri-
als are testing the potential beneficial effects of benznidazole (BZ) in chronic Chagas disease. The Argentine company Elea Laboratories is 
manufacturing the generic version of BZ under the tradename Abarax. Paediatric formulations of BZ and nifurtimox are being implemented. 
BENEFIT: Benznidazole Evaluation for Interrupting Trypanosomiasis; BERENICE: Benznidazole and Triazole Research Group for Nanomedi-
cine and Innovation on Chagas Disease; Broad: Broad Institute; DDU@Dundee: Drug Discovery Unit at Dundee University; DNDi: Drugs for 
Neglected Diseases initiative; GNF: Genomics Institute of the Novartis Research Foundation; IPK: Institute Pasteur Korea; LSTMH: London 
School of Tropical Medicine & Hygiene; NYU: New York University; STPH: Swiss Tropical and Public Health Institute; TRAENA: Tratami-
ento con Benznidazol en pacientes Adultos con Enfermedad de Chagas Crónica; UGA: University of Georgia.
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Currently, several typing approaches for DTU as-
signment of T. cruzi populations are available and man-
ageable in laboratories in endemic areas (Zingales et al. 
2012). T. cruzi DTUs have distinct, but not exclusive eco-
logical and epidemiological associations (Table). Corre-
lation of the clinical presentation of chronic Chagas dis-
ease with DTUs is circumstantial, but not proven and is 
complicated by the occurrence of mixed infections, se-
questration of DTUs in tissues and complex interactions 
with the host immune response (Vago et al. 2000, Miles 
et al. 2009, Urbina 2010, Zingales et al. 2012). Chagasic 
cardiomyopathy and ECG abnormalities occur through-
out endemic regions; megaoesophagus and megacolon 
are considered to be common in the Southern Cone and 
rare north of the Amazon (Miles et al. 2009, Guhl & 
Ramírez 2011, Zingales et al. 2012).
The Drugs for Neglected Diseases initiative (DNDi) 
has been interested in understanding the impact of T. cru-
zi genetic diversity for R&D of new treatments for Chagas 
disease. Accordingly, a group of experts convened during 
the Chagas Clinical Research Platform Meeting, spon-
sored by DNDi on 23 September 2012 in Rio de Janeiro, 
Brazil, to establish criteria for the selection of T. cruzi 
strains for drug screening and to issue recommendations.
In arriving at the consensus recommendations, the 
following were considered:
Characteristics of T. cruzi developmental forms - 
The T. cruzi life cycle consists of three main develop-
mental forms: the “epimastigote”, which proliferates in 
the gut of triatomine vectors, the “trypomastigote”, a 
non-dividing form that has the capacity to invade mam-
malian cells and differentiates into intracellular amas-
tigotes, and the “amastigote”, which multiplies by binary 
fission in the cytoplasm of infected cells. Trypomastig-
otes arise both in the hindgut of the triatomine vector, 
termed metacyclic (infective) trypomastigotes and in the 
mammalian host. After several cycles of division, intrac-
ellular amastigotes transform to trypomastigotes, which 
destroy the cell and emerge either to invade a new host 
cell or to reach the bloodstream, from which they may 
be ingested by the insect vector. In the chronic phase of 
Chagas disease, parasitaemia is usually low and it is dif-
ficult to detect and isolate T. cruzi.
Nomenclature of T. cruzi populations - Primary iso-
late: a parasite population collected from an infected 
source (mammalian host or insect vector) and inocu-
lated into culture medium or susceptible experimental 
animals; stock: a population derived from the primary 
isolate, whose properties have not been studied; strain: 
a population with characterised biological and/or bio-
chemical parameters, maintained by serial passage in 
laboratory animals or in culture; clone: a population 
derived from a single organism. A population in which 
all individuals are considered to be genetically indis-
tinguishable is referred to as a monoclonal population, 
whereas a polyclonal population is a population com-
posed of individuals who are genetically dissimilar. Nu-
merous reports indicate that natural hosts and vectors 
may be infected with polyclonal T. cruzi populations.
DTUs and human infection - As shown in Table, 
DTUs TcI, TcII, TcV and TcVI are agents of human dis-
ease with disparate prevalence in different regions of 
Latin America (Miles et al. 2009, Guhl & Ramírez 2011, 
Zingales et al. 2012). TcI is a major human infection agent 
in Amazonia, the Andean Region, Central America and 
Mexico. Clinical presentations include chagasic cardio-
myopathy and severe cases of meningoencephalitis in 
immunocompromised hosts. Recent studies have identi-
fied a divergent group within TcI, named TcIDOM. TcIDOM 
is associated with a significant proportion of human TcI 
infections from Venezuela to northern Argentina (Cura et 
al. 2010). In the Southern Cone region of South America, 
DTUs TcII, TcV and TcVI have been associated with most 
human T. cruzi infections. Chagasic cardiomyopathy can 
be severe and a proportion of cases may develop meg-
aesophagus and megacolon (Zingales et al. 2012). TcIII is 
primarily associated with the silvatic cycle in Brazil and 
TABLE 
Summary of disease associations, geographical distribution, ecotope and host of Trypanosoma cruzi discrete typing units TcI to TcVIa
TcI The main agent of Chagas disease in the northern part of Latin America and in the Amazon Region. 
Found widely in silvatic cycles elsewhere. Many silvatic reservoirs, especially opossums  
(Didelphis). Genetically highly diverse.
TcII The principal agent of Chagas disease in Atlantic and Central Brazil. Occasionally found further 
North. Several silvatic reservoirs have been reported, but wild host species are not fully known.
TcIII Rare in human infections, sporadic in dogs. Silvatic burrowing reservoirs, especially armadillos 
(Dasypus) in South America. Some isolates have been found virulent to mice. Genetically diverse.
TcIV Secondary agent of Chagas disease in Venezuela. Arboreal (primates, raccoons)  
and terrestrial reservoirs. Silvatic, along with TcI, in North America.
TcV and TcVI Common agents of Chagas disease in the Gran Chaco/Southern Cone region. Rarely silvatic, thus 
reservoirs, if any, are poorly known. Possible anthropogenic or peridomestic origins. Both genetically 
conserved. Recent hybrids of TcII and TcIII.
a: information compiled from Miles et al. (2009), Guhl and Ramírez (2011) and Zingales et al. (2012).
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adjacent countries and documented human infections are 
rare. Human TcIV infections are sporadic in Venezuela 
and uncommon in other countries (Zingales et al. 2012).
DTUs and natural resistance to BZ and NF - No ap-
parent DTU association with epimastigote natural re-
sistance to BZ and NF has been observed, which is in 
contrast to reports for trypanocidal activities of novel 
macrolide antibiotics (Aquilino et al. 2012).
Drug screening capacity - In vitro drug screening 
capacity depends on many factors, mainly parasite stage 
used, length of assay, type of readout (image-based vs. 
colorimetric/fluorescence/luminescence-based) and, par-
ticularly, available equipment and resources. Although 
costly and available to few laboratories, high throughput 
screening currently provides the most sophisticated rea-
dout (Engel et al. 2010, Nohara et al. 2010). Genetically 
engineered parasites can offer improved read out of ac-
tivities (Buckner et al. 1996).
Recommendations for the discovery and develop-
ment of new drug candidates - By consensus, the authors 
recommend that surveys of new anti-trypanosomal can-
didates should consider the following guidelines: 
(i) Screening should be performed on intracellular 
amastigotes. Epimastigote screening is much less ex-
pensive, but the results may be unrelated to efficacy 
against the amastigote stage. Differences in BZ and NF 
potency against axenic epimastigotes and intracellular 
stages have been reported (Neal & van Bueren 1988). In 
amastigote screening, the infectivity and fitness of the 
clone/strain are the main factors behind the robustness 
and performance of the assay.
(ii) If resources allow, primary screens should ide-
ally be performed against two clones/monoclonal strains. 
High throughput screening may be limited to a single 
clone/strain. Priority should be given to clones/strains 
belonging to DTUs more often associated with human 
infection (TcIDOM, TcII, TcV and TcVI). The choice of bio-
logical clones is justified as they are genetically and phe-
notypically well-characterised organisms and constitute a 
more homogeneous population. A list of clones of differ-
ent DTUs is available (Zingales et al. 2009). Laboratory 
strains displaying a monoclonal population structure may 
also be advantageous, as competition between clones of 
polyclonal strains is known to occur and clone selection 
may compromise assay performance and reproducibility.
(iii) Once promising drug candidates have been iden-
tified, they should be checked for broad activity against 
two or three representatives of each DTU (secondary 
screens). Priority should be given to DTUs that are more 
often associated with human infection (TcIDOM, TcII, 
TcV and TcVI), preferably with dissimilar characteris-
tics regarding geographical origin, replication rates, as 
this parameter may impact the response to some classes 
of drugs, and level of susceptibility to BZ or NF. This 
last item is particularly relevant when any drug candi-
dates are analogues of BZ and/or NF. An extensive list of 
strains reports susceptibility and natural resistance to the 
two drugs (Filardi & Brener 1987). There is a large panel 
of clones representing the different DTUs, from which 
examples are available for comparison of in vitro drug 
susceptibility (Lewis et al. 2009, Moraes et al. 2014).
(iv) Genetically modified parasites may be used for 
drug screening if the genetic modification does not lead to 
major phenotypic changes compared to the parental clone/
strain. Transgenic strains expressing the Escherichia coli 
β-galactosidase gene, the firefly luciferase, the tandem 
tomato fluorescent protein and the green fluorescent pro-
tein are available (Buckner et al. 1996, Canavaci et al. 
2010, Bustamante & Tarleton 2011).
Concluding remarks - Activities regarding Cha-
gas disease drug discovery depend largely on a limited 
number of academic groups. Consequently, little litera-
ture is available to support choices between models and 
different groups often rely on their own in vitro and in 
vivo models to discover and advance lead compounds 
and drug candidates. Here, we present an approach to the 
standardisation of one important aspect of Chagas dis-
ease drug discovery: the choice of T. cruzi strains and 
clones for in vitro screening. In vitro screens against a 
panel of strains and clones representing T. cruzi genetic 
diversity appear to be lacking in most Chagas disease 
drug discovery programmes, but we consider it to be a 
valuable component of the early assessment of promising 
drug candidates. However, we do not suggest that such 
comparisons of DTU susceptibilities must be performed 
before any evaluation of drug candidates in in vivo ani-
mal models. While the assessment of in vitro drug activ-
ity against members of different DTUs does not guaran-
tee drug success in humans, divergent activities among 
the strains could indicate the likelihood of failure. Thus, 
screening against several parasite lineages would provide 
better grounds - but not necessarily a filter - for decisions 
on which compounds should and should not be advanced 
or how much further characterisation of a compound’s 
anti-parasitic activity is needed before it can be advanced. 
Another advantage of performing in vitro assays is that 
they might allow a more straightforward evaluation of a 
strain/clone’s “natural” resistance to a compound, as in 
vitro assays have fewer variables than in vivo models.
The vast majority of studies for in vivo drug screen-
ing use mouse models. Although the tools for in vivo 
screening have improved dramatically in the last few 
years (Bustamante & Tarleton 2011), this system is im-
practical for the scrutiny of large compound libraries or 
analysis of the behaviour of several T. cruzi strains. Fur-
ther validation of including representatives of the DTUs 
in in vitro assays of drug susceptibility testing will de-
pend on the outcome of more in vitro studies, such as 
that of Moraes et al. (2014) and on focused and well con-
trolled in vivo comparisons to increase understanding of 
the influence of T. cruzi genetic diversity on treatment 
outcome, which may be aided by in vivo biolumines-
cence imaging (Lewis et al. 2014).
In conjunction with high priority research on treat-
ment for Chagas disease, the development of diagnostic 
tests for early determination of therapeutic responses 
and cure is urgently required (WHO 2012). A Strategic 
Translation Award from The Wellcome Trust is fund-
ing a three-year study to identify new biological mark-
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ers for the evaluation of therapeutic response in Chagas 
disease (Figure). The WHO, the Special Programme for 
Research and Training in Tropical Diseases and the Pan-
American Health Organization have sponsored an in-
ternational study to evaluate polymerase chain reaction 
(PCR) methods detecting T. cruzi DNA in blood samples 
of patients with Chagas disease (Schijman et al. 2010). 
Further work is still needed to validate these methods 
through prospective studies in different settings, such as 
post-treatment follow-up. Nevertheless, alternatives to 
PCR are clearly needed.
Especially with the benefit of new drugs, interna-
tional consensus is required to scale up diagnosis and 
treatment, to define criteria for treatment and to provide 
access to drugs. Currently, treatment coverage for Cha-
gas disease patients is unacceptably low because many 
guidelines exclude chronic patients who are undoubtedly 
the most vulnerable majority.
For efficient R&D, highly effective collaborations are 
required to optimise use of limited funding. Continued 
efforts to focus and improve drug discovery will greatly 
benefit both the research community and the population 
burdened with Chagas disease.
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Drug discovery for Chagas disease • Bianca Zingales et al. 1
Chagas disease drug discovery and development landscape in 2013/2014. Research activities: public and private partners are engaged in the 
screening of chemical libraries, hit to lead and lead optimisation of new series for Chagas disease treatment; Translational activities: pre-clinical 
studies, Phase I and IIa studies with new compounds are underway; Development activities: two double-blind, placebo-controlled clinical tri-
als are testing the potential beneficial effects of benznidazole (BZ) in chronic Chagas disease. The Argentine company Elea Laboratories is 
manufacturing the generic version of BZ under the tradename Abarax. Paediatric formulations of BZ and nifurtimox are being implemented. 
BENEFIT: Benznidazole Evaluation for Interrupting Trypanosomiasis; BERENICE: Benznidazole and Triazole Research Group for Nanomedi-
cine and Innovation on Chagas Disease; Broad: Broad Institute; DDU@Dundee: Drug Discovery Unit at Dundee University; DNDi: Drugs for 
Neglected Diseases initiative; GNF: Genomics Institute of the Novartis Research Foundation; IPK: Institute Pasteur Korea; LSTMH: London 
School of Tropical Medicine & Hygiene; NYU: New York University; STPH: Swiss Tropical and Public Health Institute; TRAENA: Tratami-
ento con Benznidazol en pacientes Adultos con Enfermedad de Chagas Crónica; UGA: University of Georgia.
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